{
    "clinical_study": {
        "@rank": "142837", 
        "acronym": "IMAGINE 7", 
        "arm_group": [
            {
                "arm_group_label": "LY2605541 Fixed Dosing", 
                "arm_group_type": "Experimental", 
                "description": "LY2605541 administered subcutaneously (SQ) at approximately the same time every evening for 12 weeks."
            }, 
            {
                "arm_group_label": "LY2605541 Variable Dosing", 
                "arm_group_type": "Experimental", 
                "description": "LY2605541 administered SQ on a variable schedule for 12 weeks.  Dosing times should remain approximately the same throughout the 12 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "The primary purpose of participation in this study is to compare the safety and efficacy of\n      different dosing schedules of LY2605541 and how different dosing schedules of LY2605541\n      affect Hemoglobin A1c (HbA1c).  Participants will be treated for up to 36 weeks with\n      LY2605541 (one 12-week Lead-in period and two 12-week Randomization periods) and 42 weeks\n      total study enrollment (10 day screening period and 4 week Follow-up period)."
        }, 
        "brief_title": "A Study of LY2605541 in Participants With Type 1 Diabetes Mellitus", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "condition": "Type 1 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 1"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Type 1 diabetes mellitus for at least one year\n\n          -  Have an HbA1c value <9.0%\n\n          -  Have a Body Mass Index (BMI) \u226435.0 kilogram per square meter (kg/m^2)\n\n          -  Currently using basal/ bolus insulin\n\n          -  Women of childbearing potential are not breastfeeding and must use methods to prevent\n             pregnancy\n\n        Exclusion Criteria:\n\n          -  Have excessive insulin resistance\n\n          -  Taking medications other than insulin for diabetes\n\n          -  High triglycerides\n\n          -  Have had more than 1 episode of severe hypoglycemia (defined as requiring assistance\n             due to neurologically disabling hypoglycemia as determined by the investigator)\n             within 6 months prior to entry into the study\n\n          -  Have had 2 or more emergency room visits or hospitalizations due to poor glucose\n             control (hyperglycemia or diabetic ketoacidosis) in the past 6 months\n\n          -  Have cardiac disease with functional status that is New York Heart Association (NYHA)\n             Class III or IV (per NYHA Cardiac Disease Classification)\n\n          -  Impaired renal function\n\n          -  Impaired liver function\n\n          -  Have had a blood transfusion or severe blood loss within 3 months prior to screening\n             or have known hemoglobinopathy, hemolytic anemia, or sickle cell anemia, or any other\n             traits of hemoglobin abnormalities known to interfere with HbA1c measurement\n\n          -  Cancer, recent cancer, or risk of cancer\n\n          -  Have known hypersensitivity or allergy to any of the study insulins or their\n             excipients\n\n          -  Chronic systemic glucocorticoid use\n\n          -  Clinically significant diabetic autonomic neuropathy\n\n          -  Have irregular sleep/wake cycle\n\n          -  Have been treated with a drug within the last 30 days that has not received\n             regulatory approval at the time of study entry\n\n          -  Prior study participation\n\n          -  Are using or have used niacin preparations as a lipid-lowering medication and/or bile\n             acid sequestrants within 90 days prior to screening"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "170", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01792284", 
            "org_study_id": "14184", 
            "secondary_id": "I2R-MC-BIAX"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "LY2605541 Fixed Dosing", 
                    "LY2605541 Variable Dosing"
                ], 
                "description": "Administered SQ", 
                "intervention_name": "LY2605541", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "LY2605541 Fixed Dosing", 
                    "LY2605541 Variable Dosing"
                ], 
                "description": "All participants will be administering insulin lispro SQ as their pre-meal insulin during the course of the trial.", 
                "intervention_name": "Insulin Lispro", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Insulin LISPRO", 
                "Insulin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 30, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Concord", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94520"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Escondido", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92026"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fresno", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "93720"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tustin", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92780"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aurora", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80045"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Roswell", 
                        "country": "United States", 
                        "state": "Georgia", 
                        "zip": "30076"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Idaho Falls", 
                        "country": "United States", 
                        "state": "Idaho", 
                        "zip": "83404"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Crystal Lake", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60012"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Des Moines", 
                        "country": "United States", 
                        "state": "Iowa", 
                        "zip": "50314"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Topeka", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "66606"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lexington", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40503"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oklahoma", 
                        "country": "United States", 
                        "state": "Oklahoma", 
                        "zip": "73104"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Greer", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29651"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chattanooga", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37411"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Austin", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78731"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75230"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Round Rock", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78681"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bayamon", 
                        "country": "Puerto Rico", 
                        "zip": "00961"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Puerto Rico"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Comparison of LY2605541 Once Daily at a Fixed Time With LY2605541 Variable Time of Dosing in Participants With Type 1 Diabetes Mellitus: An Open Label, Randomized, Crossover Study", 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Hemoglobin A1c (HbA1c) at 12 Weeks", 
            "safety_issue": "No", 
            "time_frame": "12 Weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01792284"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "30-Day Adjusted Rate of Total and Nocturnal Hypoglycemic Events", 
                "safety_issue": "Yes", 
                "time_frame": "Randomization through 12 Weeks"
            }, 
            {
                "measure": "Fasting Blood Glucose (FBG) Measured by Self-Monitored Blood Glucose", 
                "safety_issue": "No", 
                "time_frame": "12 Weeks"
            }, 
            {
                "measure": "Intra-Participant Variability of FBG", 
                "safety_issue": "No", 
                "time_frame": "12 Weeks"
            }, 
            {
                "measure": "Change from Randomization to 12 Weeks in Fasting Serum Glucose", 
                "safety_issue": "No", 
                "time_frame": "Randomization, 12 Weeks"
            }, 
            {
                "measure": "Change from Randomization to 12 Weeks in 9-Point Self-Monitored Blood Glucose", 
                "safety_issue": "No", 
                "time_frame": "Randomization, 12 Weeks"
            }, 
            {
                "measure": "Change from Randomization to 12 Weeks in Body Weight", 
                "safety_issue": "No", 
                "time_frame": "Randomization, 12 Weeks"
            }, 
            {
                "measure": "Change from Randomization to 12 Weeks in HbA1c", 
                "safety_issue": "No", 
                "time_frame": "Randomization, 12 Weeks"
            }, 
            {
                "measure": "Basal, Bolus, and Total Insulin Doses at 12 Weeks", 
                "safety_issue": "No", 
                "time_frame": "12 Weeks"
            }, 
            {
                "measure": "Change in Anti-LY2605541 Antibodies", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline through 36 Weeks"
            }, 
            {
                "measure": "0300-Hour Blood Glucose to Fasting Blood Glucose Excursion", 
                "safety_issue": "No", 
                "time_frame": "12 Weeks"
            }, 
            {
                "measure": "Triglycerides, Total Cholesterol, Low-Density Lipoprotein (LDL-C), and High-Density Lipoprotein Cholesterol (HDL-C)", 
                "safety_issue": "Yes", 
                "time_frame": "Randomization and 12 Weeks of Each LY2605541 Regimen"
            }, 
            {
                "measure": "Proportion of Participants with HbA1c <7.0% and \u22646.5% at 12 Weeks", 
                "safety_issue": "No", 
                "time_frame": "12 Weeks"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}